Update on the use of defibrotide

Bibliography

• Benimetskaya L, Wu S, Voskresenskiy A, Angiogenesis-alteration by Defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Blood 2008;112:4343-52
   PubMed Web of Science ®Google Scholar
• Echart C, Graziadio B, Somaini S, The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity. Blood Coagul Fibrinolysis 2009;20:627-34
   PubMed Web of Science ®Google Scholar
• Falanga A, Vignoli A, Marchetti M, Barbui T. Defibrotide reduces activity and increases fibrinolytic properties of endothelial cells. Leukemia 2003;17:1636-42
   PubMed Web of Science ®Google Scholar
• Zhou Q, Chu X, Ruan C. Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thromb Haemost 1994;71:507-10
   PubMed Web of Science ®Google Scholar
• Jamieson A, Alcock P, Wood L, Tuffin DP. Effect of the deoxyribonucleic acid derivative Defibrotide on plasma fibrinolytic activity in the rat [abstract]. Br J Pharmacol 1992;106(Suppl):89P
   Google Scholar
• Jamieson A, Alcock P, Tuffin DP. The action of polyanionic agents Defibrotide and pentosan sulphate on fibrinolytic activity in the laboratory rat. Fibrinolysis 1996;10:27-35
   Google Scholar
• Klocking HP. Acute t-PA release by defibrotide. Thromb Res 1992;66:779-85
   PubMed Web of Science ®Google Scholar
• Nunziata A, Mariani FM, Cascone M, Increased plasma t-PA activity and urinary PGE2 after repeated oral administration of Defibrotide to the rat and the mouse. Thromb Res 1991;64:279-84
   PubMed Web of Science ®Google Scholar
• Kornblum N, Kanyalakshmi A, Benitmeskaya L, Defibrotide, a polydisperse mixture of single- stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic venoocclusive disease: clinical outcomes and potential mechanisms of action. Oligonucleotides 2006;16:105-14
   PubMed Web of Science ®Google Scholar
• Pellegatta F, Lu Y, Radaelli A, Drug-induced in vitro inhibition of neutrophil-endothelial cell adhesion. Br J Pharmacol 1996;118:471-6
   PubMed Web of Science ®Google Scholar
• Carlo-Stella C, Di Nicola M, Magni M, Defibrotide in combination with granulocyte colony stimulating factor significantly enhances the mobilization of primitive and committed peripheral blood progenitor cells in mice. Cancer Res 2002;62:6152-7
   PubMed Web of Science ®Google Scholar
• Carlo Stella C, Di Nicola M, Longoni P, Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with Defibrotide and recombinant human granulocyte colony-stimulating factor. Exp Hematol 2004;32:68-75
   PubMed Web of Science ®Google Scholar
• Bianchi G, Barone D, Lanzarotti E, Defibrotide, a single-stranded polydeoxiribonucleotide acting a san adenosine receptor agonist. Eur J Pharmacol 1993;238:327-34
   PubMed Web of Science ®Google Scholar
• Eissner G, Multhoff G, Gerbitz A, Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood 2002;100:334-40
   PubMed Web of Science ®Google Scholar
• Schroder H. Defibrotide protects endothelial cells, but not L929 tumour cells, from tumour necrosis factor-alpha-mediated cytotoxicity. J Pharm Pharmacol 1995;47:250-2
   PubMed Web of Science ®Google Scholar
• Benimetskaya I, Wu S, Voskresensky AM, Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Blood 2008;112:4343-52
   PubMed Web of Science ®Google Scholar
• Palomo M, Diaz-Ricart M, Rovira M, Defibrotide prevents the activation of macrovascular and microvascular endothelia caused by soluble factors released to blood by autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011;17:497-506
   PubMed Web of Science ®Google Scholar
• McDonald GB, Hinds MS, Fisher LD, Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993;118:255-67
   PubMed Web of Science ®Google Scholar
• Carreras E, Bertz H, Arcese W, Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998;92:3599-604
   PubMed Web of Science ®Google Scholar
• Richardson P, Guinan E. The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches. Br J Haematol 1999;107:485-93
   PubMed Web of Science ®Google Scholar
• Richardson P, Guinan E. Hepatic veno-occlusive disease following hematopoietic stem cell transplantation. Acta Haematol 2001;106:57-68
   PubMed Web of Science ®Google Scholar
• Shulman HM, Fisher LB, Schoch HG, Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 1994;19:1171-8
   PubMed Web of Science ®Google Scholar
• Ho VT, Linden E, Revta C, Richardson PG. Hepatic veno-occlusive disease following high dose chemotherapy and stem cell transplantation: review and update on the use of defibrotide and other current investigational therapies. Semin Thromb Hemost 2007;33:373-88
   PubMed Web of Science ®Google Scholar
• Shulman HM, McDonald GB, Matthews D, An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology 1980;79:1178-97
   PubMed Web of Science ®Google Scholar
• Shulman HM, Gown AM, Nugent DJ. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol 1987;127:549-58
   PubMed Web of Science ®Google Scholar
• Pihusch R, Salat C, Scmidt E, Hemostatic complication in bone marrow transplantation: a retrospective analysis of 447 patients. Transplantation 2002;74:1303-9
   PubMed Web of Science ®Google Scholar
• Bearman SI, Anderson GL, Mori M, Veno occlusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993;11:1729-36
   PubMed Web of Science ®Google Scholar
• Lee JL, Gooley T, Bensinger W, Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 1999;17:306-15
   Google Scholar
• Hogan WJ, Maris M, Storer B, Hepatic injury after non myeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 2004;103:78-84
   PubMed Web of Science ®Google Scholar
• Mc Donald GB. Veno-occlusive disease of the liver following marrow transplantation. Bone Marrow Transplant 1993;3:49-56
   Google Scholar
• Rozman C, Carreras E, Qian C, Risk factors for hepatic veno-occlusive disease following HLA identical sibling bone marrow transplantation for leukemia. Bone Marrow Transplant 1996;17:75-80
   PubMed Web of Science ®Google Scholar
• Nevill TJ, Barnett MJ, Klingemann HG, Regimen-related toxicity of a busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplanatation. J Clin Oncol 1991;9:1224-32
   PubMed Web of Science ®Google Scholar
• Matute-Bello G, Mc Donald GB, Hinds MS, Association of pulmonary function testing abnormalities and severe veno-occlusive disease of the liver after marrow transplantation. Bone Marrow Transplant 1998;21:1125-30
   PubMed Web of Science ®Google Scholar
• Richardson PG, Elias AD, Krishnan A, Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998;92:737-44
   PubMed Web of Science ®Google Scholar
• Chopra R, Eaton JD, Grassi A, Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000;111:1122-9
   PubMed Web of Science ®Google Scholar
• Richardson PG, Murakami C, Jin Z, Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002;100:4337-43
   PubMed Web of Science ®Google Scholar
• Corbacioglu S, Greil J, Peters C, Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant 2004;33:189-95
   PubMed Web of Science ®Google Scholar
• Richardson P, Soiffer RJ, Antin JH, Defibrotide for the treatment of severe veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant 2010;16:1005-17
   PubMed Web of Science ®Google Scholar
• Richardson P, Tomblyn M, Kernan N, Defibrotide in the treatment of severe hepatic veno-occlusive disease with multi-organ failure following stem cell transplantation: results of a phase 3 study utilizing a historical control [abstract]. Blood 2009;114(22):654
   Web of Science ®Google Scholar
• Richardson PG, Smith AR, Grupp SA, Defibrotide in the treatment of hepatic veno-occlusive disease in stem cell transplant and non-SCT patients.early intervention improves outcome- Updated results of a teatment IND expanded access protocol [abstract]. Blood 2011;118(21):487
   PubMedGoogle Scholar
• Versluys B, Bhattacharaya R, Steward C, Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. Blood 2004;103(5):1968
   PubMed Web of Science ®Google Scholar
• Corbacioglu S, Honig M, Lahr G, Stem cell transplantation in children with infantile osteopetrosis is associated with high incidence of VOD which could be prevented by defibrotide. Bone Marrow Transplant 2006;38:547-53
   PubMed Web of Science ®Google Scholar
• Chalandon Y, Roosnek E, Mermillod B, Prevention of veno.occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004;10:347-54
   PubMed Web of Science ®Google Scholar
• Dignan F, Gujral D, Erhell M, Prophylactic defibrotide in allogeneic cell transplantation:minimal morbidity and zero mortality from veno occlusive disease. Bone Marrow Transplant 2007;40:79-82
   PubMed Web of Science ®Google Scholar
• Bonini A, Avanzini P, Masini L, Defibrotide low-dose continuous infusion from day +1 until day +21 after allogeneic stem cell transplantation as prophylaxis of veno-occlusive disease (VOD) of the liver. A single centre experience [abstract]. Blood 2007;110(11):4927
   Google Scholar
• Milone G, Poidomani M, Coppoletta S, Defibrotide in prevention of liver toxicity in patients at high risk of VOD after HSC transplantation [abstract]. Blood 2008;112(11):3275
   Google Scholar
• Qureshi A, Marshall L, Lancaster D. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children. Pediatr Blood Cancer 2008;50:831-2
   PubMed Web of Science ®Google Scholar
• Cappelli B, Chiesa R, Evangelio C, Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan. Br J Haematol 2009;147:554-60
   PubMed Web of Science ®Google Scholar
• Corbaciouglu S, Cesaro S, Faraci M, Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicentre study [abstract]. Bone Marrow Transplant 2010;45(S2):abstract 70
   Google Scholar
• EA AKL, Labedi N, Barba M, Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2011;(6):CD006650
   Google Scholar
• Mitsiades CS, Rouleau C, Echart C. Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. Clin Cancer Res 2009;15:1210-21
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med JID 1995;1:27-31
   PubMed Web of Science ®Google Scholar
• Morabito A, Sarmiento R, Bonginelli P, Gasparini G. Antiangiogenic strategies, compounds, and early clinical result in brast cancer. Crit Rev Oncol Hematol 2004;49:91-107
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-60
   PubMed Web of Science ®Google Scholar
• Gottfried E, Kreutz M, Haffner S, Differentiation of human tumour-associated dendritic cells into endothelial-like cells: an alternative pathway of tumour angiogenesis. Scand J Immunol 2007;65:329-35
   PubMed Web of Science ®Google Scholar
• Koehl GE, Geissler EK, Iacobelli M, Defibrotide an endothelium protecting and stabilizing drug has an anti-angiogenic potential in vitro and in vivo. Cancer Biol Ther 2007;65:686-90
   Google Scholar
• Van Kempen LC, Ruiter DJ, van Muijen GN, Coussens LM. The tumor microenvironment:a critical determinant of neoplastic evolution. Eur J Cell Biol 2003;82:539-48
   PubMed Web of Science ®Google Scholar
• Zhou J, Mauerer K, Farina L, Gribben JG. The role of the tumor microenvironment in hematologic malignancies and implication for therapy. Front Biosci 2005;10:1581-96
   PubMed Web of Science ®Google Scholar
• Bogdanos J, Karamanolakis D, Tenta R, Endocrine/paracrine/autocrine survival factor activity of bone microenvironment partecipates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton. Endocr Relat Cancer 2003;10:279-89
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, McMillin DW, Klippel S, The role of the bone marrow microenvironment in the pahophysiology of myeloma and its significance in the development of more effctive therapies. Hematol Oncol Clin North Am 2007;21:1007-34
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Rouleau C, Menon K. Defibrotide target tumour-microenvironmental interaction and sensitizes multiple myeloma and solid tumour cells to cytotoxic chemotherapeutics [abstract]. Blood 2004;104:286
   Google Scholar
• Mitsiades CS, Benimetskaya I, Menon K, Defibrotide, an orally bioavalaible modulator of myeloma tumor microenvironment interactions: molecular sequelae and clinical implications [abstract]. Blood (ASH) 2006;108:3523
   Google Scholar
• Echart C, Distaso M, Ferro L, Defibrotide induces downregulation of heparanase expression in multiple myeloma cell lines: a novel mechanisms of action. Hematologica 2007;92(6 Suppl 2):146
   Web of Science ®Google Scholar
• Mitsiades CS, Rouleau C, Echart C. Preclinical studies in support of defibrotide for the the treatment of multiple myeloma and othe neoplasia. Clin Cancer Res 2009;15:1210-21
   PubMed Web of Science ®Google Scholar
• Echart CL, Somaini BS, Distaso M, Defibrotide blunts the prothrombotic effect of thalidomide on endothelial cells. Clin Appl Thromb Hemost [Epub ahead of print: 6 July 2011; doi: 10.1177/1076029611412367]
   PubMed Web of Science ®Google Scholar
• Palumbo A, Larocca A, Genuardi G. Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. Haematologica 2010;95:1144-9
   PubMed Web of Science ®Google Scholar